No Data
No Data
Knight Therapeutics Inc. (TSE:GUD) Most Popular Amongst Individual Investors Who Own 41% of the Shares, Institutions Hold 24%
Knight Therapeutics Says Health Canada Accepts ADHD Drug Application for Review
Express News | Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (Viloxazine) in Canada
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree (Viloxazine) in Canada
Knight Therapeutics Brief: Announced Health Canada Approval for JORNAY PM to Treat Attention-Deficit Hyperactivity Disorder
Knight Therapeutics Inc Price Target Cut to C$7.50/Share From C$8.00 by Raymond James